Changes in the level of blood glucose in patients at the 3rd stage of cardiorehabilitation after acute coronary syndrome
Abstract
Retrospective study of changes in metabolic status indicators (carbon and lipid metabolism, body mass) in patients at the 3rd stage of cardio-rehabilitation after acute coronary syndrome was conducted.
About the Authors
I. V. Druk
ФГБОУ ВО ОмГМУ МЗ РФ
Russian Federation
Russian Federation
O. Yu. Korennova
ФГБОУ ВО ОмГМУ МЗ РФ
Russian Federation
Russian Federation
M. V. Savchenko
БУЗОО ККД
Russian Federation
Russian Federation
S. P. Podolnaya
БУЗОО ККД
Russian Federation
Russian Federation
M. M. Ibragimova
ФГБОУ ВО ОмГМУ МЗ РФ
Russian Federation
Russian Federation
K. A. Neumerzhitskaya
ФГБОУ ВО ОмГМУ МЗ РФ
Russian Federation
Russian Federation
References
1. Дедов И. И., Шестакова М. В., Галстян Г. Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION) // Сахарный диабет. 2016; 19 (2): 104-112.
2. Корнеева М. Н., Поддубская Е. А., Марданов Б. У., Дудинская Е. Н. Ранние нарушения углеводного обмена в кардиологической практике: диагностика и лечение: пособие / Под ред. М. Н. Мамедова. М.: ФГБУ Государственный научно-исследовательский центр профилактической медицины, 2017. 108 с., илл.
3. Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений. Совет экспертов // Российский кардиологический журнал. 2019; 24 (4): 83-91. dx.doi.org/10.15829/1560-4071-2019-4-83-91.
4. Geng D.-F., Jin D.-M., Wu W. et al. Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A metaanalysis of 72 128 patients // Int. J. Cardiol. 2013. Vol. 167 (6). P. 2605-2610.
5. Song H. F., Wang S., Li H. W. Eff ect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials // Chinese Med. J. 2012. Vol. 125 (10). P. 1804-1810.
6. Dezs C. A. The Diff erent Th erapeutic Choices with ARBs. Which One to Give? When? Why? // Am. J. Cardiovasc. Drugs. 2016. Vol. 16. P. 255-266.
7. Liou Yi.-S., Chen H.-Yi., Tien L. et al. Antihypertensive Drug Use and New-Onset Diabetes in Female Patients with Coronary Artery Disease. A Population-based Longitudinal Cohort Study // Medicine. 2015. Vol. 94 (36). e1495.
8. Grimm C., Koberlein J., Wiosna W. New-onset diabetes and antihypertensive treatment // GMS Health Technol. Assess. 2010. Vol. 6. DOI: 10.3205/hta000081.
9. Друк И. В., Нечаева Г. И. Сахарный диабет 2-го типа для кардиологов. М.: МИА. 2017. 208 с.
10. Ripley T. L., Saseen J. J. ?-Blockers: A Review of Th eir Pharmacological and Physiological Diversity in Hypertension // Ann. Pharmacotherapy. 2014. Vol. 48, № 6. P. 723-733.
11. Catapano A. L., Graham I., Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias Th e Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS and European Atherosclerosis Society (EAS) // Eur. Heart J. 2016. Vol. 37. P. 2999-3058.
12. Preiss D., Seshasai S. R., Welsh P. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis // JAMA. 2011. Vol. 305. P. 2556-2564.
13. Mans I., Frei C. R., Wang C.-P., Mortensen E. M. Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults // J. Gen. Intern. Med. Vol. 30 (11). P. 1599-1610.
14. Sattar N., Preiss D., Murray H. M. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials // Lancet. 2010; 375: 735-742.
15. Bays H., Abate N., Chandalia M. et al. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia // Future Cardiol. 2005; 1: 39-59.
16. Яковенко Е. И., Мамендов М. Н. Влияние метаболических эффектов статинов на клинические проявления атеросклероза // Российский кардиологический журнал. 2012. 2 (94): 85-90.
17. Adhyaru B. B., Jacobson T. A. Safety and efficacy of statin therapy // Nat Rev Cardiol. 2018; 15: 757-769.
18. Grundy S. M., Stone N. J., Bailey A. L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines // J Am Coll Cardiol. 2018; pii: S0735-1097(18)39034-X.
19. Lloyd-Jones D. M., Morris P. B., Ballantyne C. M. et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk // J Am Coll Cardiol. 2017; 70: 1785-1822.
20. Brault M., Ray J., Gomez Y.-H. et al. Statin treatment and new-onset diabetes: A review of proposed mechanisms // Metabolism. 2014. Vol. 63 (6). P. 735-745.
Review
For citations:
Druk I.V., Korennova O.Yu., Savchenko M.V., Podolnaya S.P., Ibragimova M.M., Neumerzhitskaya K.A. Changes in the level of blood glucose in patients at the 3rd stage of cardiorehabilitation after acute coronary syndrome. Lechaschi Vrach. 2019;(12):38-44. (In Russ.)
Views:
226
JATS XML
Email this article 
